Logo Logo

Publications by Rugo, H. S.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 4.

Journal article

Rugo, H. S.; Dieras, V.; Gelmon, K. A.; Finn, R. S.; Slamon, D. J.; Martin, M.; Neven, P.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. Huang; Iyer, S.; Johnston, S.; Ettl, J.; Harbeck, N. (2018): Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. In: Annals of Oncology, Vol. 29, No. 4: pp. 888-894

Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; Andre, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C. H.; Bergh, J.; Biganzoli, L.; Börs-Doers, C. B.; Cardoso, M. J.; Carey, L. A.; Cortes, J.; Curigliano, G.; Dieras, V.; El Saghir, N. S.; Eniu, A.; Fallowfield, L.; Francis, P. A.; Gelmon, K.; Johnston, S. R. D.; Kaufmann, B.; Koppikar, S.; Krop, I. E.; Mayer, M.; Nakigudde, G.; Offersen, B. V.; Ohno, S.; Pagani, O.; Paluch-Shimon, S.; Penault-Llorca, F.; Prat, A.; Rugo, H. S.; Sledge, G. W.; Spence, D.; Thomssen, C.; Vorobiof, D. A.; Xu, B.; Norton, L.; Winer, E. P. (2018): 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). In: Annals of Oncology, Vol. 29, No. 8: pp. 1634-1657

Dieras, V.; Harbeck, N.; Joy, A. A.; Gelmon, K. A.; Ettl, J.; Verma, S.; Lu, D.; Gauthier, E. R.; Schnell, P.; Mori, A.; Rugo, H. S.; Finn, R. S. (2017): PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L). In: Annals of Oncology, Vol. 28

Verma, S.; DeMichele, A. M.; Loi, S.; Ro, J.; Colleoni, M.; Iwata, H.; Harbeck, N.; Stearns, V.; Cristofanilli, M.; Huang Bartlett, C.; Schnell, P.; Zhang, K.; Thiele, A.; Turner, N. C.; Rugo, H. S. (2016): Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. In: Cancer Research, Vol. 76

This list was generated on Tue Jun 2 00:39:12 2020 CEST.